MSD/Pfizer’s diabetes drug Steglatro hits goal in CV outcomes trial
The drug was shown to be as safe as placebo on a composite of CV death, nonfatal myocardial infarction or nonfatal stroke
Read More
Tag: ertugliflozin
Seven medicines leap closer to EU approval
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has put forward seven new medicines for approval in the region, including new treatment options for haemophilia A, diabetes, and a very rare genetic disorder.
Read More
US green light for Pfizer/Merck diabetes therapies
Pfizer and Merck’s diabetes drugs Steglatro and Steglujan have been approved for the US market.
Read More
Merck and Pfizer’s diabetes therapy under US, EU review
Regulators on both sides of the Atlantic are reviewing three new submissions for medicines containing ertugliflozin, an investigational SGLT2 inhibitor being developed by Merck and Pfizer to help improve glycaemic control in adults with type II diabetes.
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
